Dublin, Feb. 09, 2023 (GLOBE NEWSWIRE) -- The "Circulating Tumor Cell (CTC) Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$9.1 Billion in the year 2022, is projected to reach a revised size of US$21.3 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2022-2030.
Detection & Enrichment, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$13.8 Billion by the end of the analysis period.
Taking into account the ongoing post pandemic recovery, growth in the Analysis segment is readjusted to a revised 12.8% CAGR for the next 8-year period.
The U.S. Market is Estimated at $2.7 Billion, While China is Forecast to Grow at 10.3% CAGR
The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 9.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.
Select Competitors (Total 48 Featured) -
- ApoCell, Inc.
- Biocep Ltd.
- Biocept, Inc.
- Biofluidica Microtechnologies LLC
- Celltraffix Inc.
- Clearbridge Biomedics
- Creatv Microtech, Inc.
- Cynvenio Biosystems, Inc.
- Fluxion Biosciences, Inc.
- Ikonisys, Inc.
- IVDiagnostics, Inc.
- Janssen Diagnostics LLC
- QIAGEN Hannover GmbH
- Rarecells Sas
- Screencell
- Stemcell Technologies, Inc.
What`s New for 2023?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Report Metrics
| Report Attribute | Details |
| No. of Pages | 196 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $9.1 Billion |
| Forecasted Market Value (USD) by 2030 | $21.3 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Market Outlook
- Recent Market Activity
- Clinical Relevance of CTCs
- CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
- Major Challenges in CTC Diagnostics
- Need for CTC Enrichment and Popular Methods
- CTC Enrichment Techniques
- Select Available CTC Detection Technologies
- Select CTC Isolation Systems - A Brief Comparison
- CTC Identification - Various Approaches
- CTC Identification Approaches
- List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
- CellSearch SystemT - The First FDA Approved Automated Enrichment/Isolation Technique
- Rising Incidence of Cancer - An Opportunity Indicator
- Cancer Prone Sites based on Age
- Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Liquid Biopsy - the New Buzzword in Healthcare
- Select Companies Active in Cancer Liquid Biopsy
- CTCs for Personalized Cancer Treatment
- Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
- CTC Microdevices Hog the Limelight
- Increasing Research Reveal Further Complexities to CTC Composition and Behavior
- EpCAM Glycoprotein - Insufficient for CTC Detection
- New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
- Physical Property-based Enrichment Technologies Lose Fizz
- Evidence in Favor CTC Heterogeneity Gains Strength
- CTC Clusters Raise Research Interest
- Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
- Limitations of CTC Technology for Point-of-Care Testing
- CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
- Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
- Select Research Findings in Recent Years
- Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
- NBiomics Makes its Contribution to CTC Diagnosis
- Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
- Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
- Gold Nanoparticles Help in the Detection of CTCs
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/opclcs-tumor?w=12
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
